886363-74-2 Usage
General Description
"Ethanone,1-(5-broMo-1H-indazol-3-yl)-" refers to a specific type of organic compound that features in the classification of indazole compounds. Indazole is a type of heterocyclic aromatic compound, which forms an essential base for numerous drugs due to its varying therapeutic properties. The 5-bromo-1H-indazol-3-yl fragment of the molecule suggests bromination at the 5th position of indazole ring and the linkage at the 3rd position to a ketone existing in an ethane (similar to an acetyl) group. Details about its specific uses, properties such as solubility, polarity, toxicity or reactivity can vary and are not specified here. It is best to refer to a comprehensive substance or material safety datasheet for full information.
Check Digit Verification of cas no
The CAS Registry Mumber 886363-74-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 3 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 886363-74:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*3)+(2*7)+(1*4)=222
222 % 10 = 2
So 886363-74-2 is a valid CAS Registry Number.
InChI:InChI=1S/C9H7BrN2O/c1-5(13)9-7-4-6(10)2-3-8(7)11-12-9/h2-4H,1H3,(H,11,12)
886363-74-2Relevant articles and documents
CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS
-
Paragraph 1214-1215, (2021/03/13)
The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS
-
Paragraph 0648; 0788, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.
ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Paragraph 1199, (2017/03/14)
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
